![](/img/cover-not-exists.png)
SAT0232 A Phase 1 Clinical Trial of PRN1008, an Oral, Reversible, Covalent BTK Inhibitor Demonstrates Clinical Safety and Therapeutic Levels of BTK Occupancy Without Sustained Systemic Exposure
Smith, P.F., Krishnarajah, J., Nunn, P.A., Hill, R.J., Karr, D., Tam, D., Masjedizadeh, M., Gourlay, S.G.Volume:
74
Language:
english
Journal:
Annals of the Rheumatic Diseases
DOI:
10.1136/annrheumdis-2015-eular.4289
Date:
June, 2015
File:
PDF, 82 KB
english, 2015